Rege Nephro Co., Ltd. (Head Office: Sakyo-ku, Kyoto, Representative Director: Akifumi Morinaka) announces that we have further extended our joint research agreement signed in December 2021 with Center for iPS Cell Research and Application, Kyoto University (Headquarters: Sakyo-ku, Kyoto, Director: Jun Takahashi) and AstraZeneca (Head Office: United Kingdom) to develop a method for producing renal tissues from human induced pluripotent stem (iPS) cell-derived renal progenitor cells and to analyze their developmental biology and physiological functions in-vivo, as we have achieved remarkable results.

For more information about the project, please check out the February 2022 release.
https://www.regenephro.co.jp/en/news/2022-02-07/

«Inquiries regarding this matter»
Katsuhisa Yamaguchi
CFO, a member of Board of Directors
Rege Nephro Co., Ltd.
TEL: +81-75-744-6858
E-mail: info@regenephro.co.jp